Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis

Circulation

Volumn 101, Issue 20, 2000, Pages 2349-2354

  Prasad, Abhiram ^a,b   Tupas Habib, Theresa ^b,c   Schenke, William H ^a,b   Mincemoyer, Rita ^a,b   Panza, Julio A ^a,b   Waclawin, Myron A ^b   Ellahham, Samer ^b,c   Quyyumi, Arshed A ^a,b  

^a Cardiology Branch   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Angiotensin; Atherosclerosis; Endothelium; Losartan; Nitric oxide; Receptors

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; LOSARTAN; NITROGEN OXIDE; NITROPRUSSIDE SODIUM;

ADULT; AGED; ARTERY BLOOD FLOW; ARTERY RESISTANCE; ARTICLE; ATHEROSCLEROSIS; BLOOD FLOW VELOCITY; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; FEMORAL ARTERY; HUMAN; HYPEREMIA; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR ENDOTHELIUM;

EID: 0034705083     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.20.2349     Document Type: Article

References (37)

1. Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098-1104.
2. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
3. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.
4. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol. 1993;22(suppl 4):S1-S14.
5. Ross R. The pathogenesis of atherosclerosis: a prospective for the 1990s. Nature. 1993;362:801-809.
6. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153-2157.
7. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1067-1071.
8. Pueyo ME, Michel JB. Angiotensin II receptors in endothelial cells. Gen Pharmacol. 1997;29:691-696.
9. Griendling K, Ollerenshaw JD, Minieri CA, et al. Angiotensin II stimulates NADH and NADPH activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
10. Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest. 1996;97:1916-1923.
11. Laursen JB, Rajagopalan S, Galis Z, et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997;95:557-559.
12. Doucette JW, Corl D, Payne HM, et al. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation. 1992;85:1899-1911.
13. Husain S, Andrews NP, Mulcahy D, et al. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 1998;97:716-720.
14. Dakak N, Husain S, Mulcahy DM, et al. Contribution of nitric oxide to reactive hyperemia: impact of endothelial dysfunction and effect of L-arginine. Hypertension. 1998;32:9-15.
15. Lindsay DC, Holdright D, Clarke D, et al. Endothelial control of lower limb blood flow in chronic heart failure. Heart. 1996;75:469-476.
16. Baan J Jr, Chang PC, Vermeij P, et al. Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed of healthy volunteers. Cardiovasc Res. 1996;32:973-979.
17. Corretti MC, Plotnick GD, Vogel RA. Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol. 1995;268:H1397-H1404.
18. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothehal dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115.
19. Braman RS, Hendrix SA. Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal Chem. 1989;61:2715-2718.
20. Newby DE, Masumori S, Johnston NR, et al. Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man. Cardiovasc Res. 1997;36:268-275.
21. 1-receptor expression. Am J Physiol. 1977;272:H2701-H2707.
22. Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94: 2756-2767.
23. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996;94: 258-265.
24. Prasad A, Husain S, Quyyumi AA. Effect of enalaprilat on nitric oxide activity in coronary artery disease. Am J Cardiol. 1999;84:1-6.
25. Aversano T, Ouyang P, Silverman H. Blockade of the ATP-sensitive potassium channel modulates reactive hyperemia in the canine coronary circulation. Circ Res. 1991;69:618-622.
26. Koller A, Kaley G. Role of endothelium in reactive dilation of skeletal muscle arterioles. Am J Physiol. 1990;259:H1313-H1316.
27. Tagawa T, Imaizumi T, Endo T, et al. Role of nitric oxide in reactive hyperemia in human forearm vessels. Circulation. 1994;90:2285-2290.
28. Potter DD, Sobey CG, Tompkins PK, et al. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation. 1998;98: 800-807.
29. Seyedi N, Xu X, Nasjletti A, et al. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995;26:164-170.
30. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997;100:264-269.
31. 1 receptor antagonist irbesartan in hypertension. Hypertension. 1995;25:22-29.
32. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest. I977;99:1926-1935.
33. Jalowy A, Schulz R, Dörge H, et al. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol. 1998;32: 1787-1796.
34. Keidar S, Attias J, Smith J, et al. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 1997;236: 622-625.
35. Rodrigo E, Maeso R, Munoz-Garcia R, et al. Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. J Hypertens. 1997;15:613-618.
36. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun. 1996;226: 862-868.
37. Sudhir K, MacGregor JS, Gupta M, et al. Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature. Circulation. 1993;87:931-938.